[摘要]近年来，炎症性肠病(IBD)患者发生淋巴瘤的报道越来越多。多数研究认为IBD患者发生淋巴瘤的危险性低，但接受硫唑嘌呤(AZA)治疗的IBD患者发生淋巴瘤的危险性明显增高。目前AZA是IBD患者最常用的免疫抑制剂，其不良反应受到临床医师越来越多的关注。本文综述AZA治疗IBD患者诱发淋巴瘤的危险性、可能机制、临床获益及注意事项，以期帮助提高临床医师对该病的认识。

    [关键词]炎症性肠病;硫唑嘌呤;淋巴瘤;治疗

    [中图分类号] R574 [文献标识码] A [文章编号] 1674-4721(2020)2(b)-0019-04

    [Abstract] In recent years， there have been more and more reports of lymphoma in patients with inflammatory bowel disease (IBD). Most studies have recognized that patients with IBD have a low risk of developing lymphoma ......